Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials

Simple item page
dc.contributor.authorOrkin, Chloe
dc.contributor.authorAjana, Faiza
dc.contributor.authorKityo, Cissy
dc.contributor.authorKoenig, Ellen
dc.contributor.authorNatukunda, Eva
dc.contributor.authorGandhi-Patel, Bhumi
dc.contributor.authorWang, Hui
dc.contributor.authorLiu, Yapei
dc.contributor.authorWei, Xuelian
dc.contributor.authorWhite, Kirsten
dc.contributor.authorMakadzange, Tariro
dc.contributor.authorPikora, Cheryl
dc.contributor.authorMcNicholl, Ian
dc.contributor.authorCollins, Sean E.
dc.contributor.authorBrainard, Diana
dc.contributor.authorChuck, Susan K.
dc.date.accessioned2022-05-08T10:48:19Z
dc.date.available2022-05-08T10:48:19Z
dc.date.issued1999
dc.description.abstractWe characterized the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a broad population of pediatric/adolescent/adult/elderly females living with HIV (FWH). Setting: Integrated analysis. Methods: Available data from 5 trials were integrated. Week 48 virologic suppression (HIV-1 RNA ,50 copies/mL), resistance, adverse events (AEs), and laboratory parameters were assessed. Results: Three hundred and seventy-three FWH [304 virologically suppressed; 69 antiretroviral therapy (ART)-naive] received B/F/TAF [data from comparator regimens available for 306 individuals (236 virologically suppressed and 70 ART-naive participants)]. Virologic suppression rates with B/F/TAF at week 48 were high regardless of age in participants virologically suppressed at baseline ($95%) and in ART-naive participants ($87%). Virologic suppression rates were similar in B/F/TAF and comparator regimens (both virologically suppressed and ART-naive groups). Treatment-emergent resistance was not detected in the B/F/TAF group. AEs considered related to study drugs were experienced by 9.2% (B/F/TAF) and 5.5% (comparator regimen) of virologically suppressed participants and 15.9% (B/F/TAF) and 31.4% (comparator regimen) of ART-naive participants. For virologically suppressed and ART-naive FWH combined, only 1 of the 373 B/F/TAF–treated and 2 of the 306 comparator-regimen participants discontinued because of AEs (none were bone/renal/hepatic AEs); grade 3/4 AEs were experienced by 5.1% (B/F/TAF) and 7.8% (comparator regimen); and grade 3/4 elevation of low-density lipoprotein/total cholesterol occurred in 2.7%/ 0.3% (B/F/TAF) and 5.9%/2.0% (comparator regimen). At week 48, median changes from baseline estimated glomerular filtration rate in adults were ,5 mL/min; results were similar in B/F/TAF and comparator-regimen groups. Conclusion: B/F/TAF treatment was effective and well tolerated over 48 weeks, confirming B/F/TAF as an option for a broad population of FWH.en_US
dc.identifier.citationOrkin, C., Ajana, F., Kityo, C., Koenig, E., Natukunda, E., Gandhi-Patel, B., ... & Chuck, S. K. (2021). Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. Journal of Acquired Immune Deficiency Syndromes (1999).en_US
dc.identifier.urihttps://europepmc.org/article/pmc/pmc8547745
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/3209
dc.language.isoenen_US
dc.publisherJournal of Acquired Immune Deficiency Syndromesen_US
dc.subjectFemaleen_US
dc.subjectBictegraviren_US
dc.subjectEmtricitabineen_US
dc.subjectChilden_US
dc.subjectHIVen_US
dc.subjectAdolescenten_US
dc.titleEfficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trialsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Brief_Report__Efficacy_and_Safety_of.11.pdf
Size:
124.88 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences